Obesity drugs would be covered by Medicare and Medicaid under Biden administration proposal

Contributing sentiments towards policy:

50% : The proposal would help an estimated 3.4 million people on Medicare and 4 million people on Medicaid prescription gain coverage for these drugs, according to the White House.
50% : This population makes up about 7% of those on Medicare, according to a KFF analysis released in April.
48% : "This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation," the administration said.Ozempic and Wegovy, from Novo Nordisk, and Mounjaro an Zepbound, from Eli Lilly, are not currently covered by Medicare because a decades-old law prevents the federal program from covering weight-loss drugs.
47% : Coverage of these drugs have been an optional drug benefit for Medicaid programs, according to the Centers for Medicare and Medicaid Services.
41% : Among the approximately 13.7 million people on Medicare who are diagnosed obese or overweight, about 3.6 million also have cardiovascular disease.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.